Saxenda (liraglutide) Weight Loss Pens: Everything You Need to Know

Searching for a medically supervised, prescription option to help with weight management? Saxenda (liraglutide) is one of the prescription medicines available in the UK that can support weight loss when used alongside diet, physical activity and behavioural changes. This long, detailed guide explains how Saxenda works, who it’s for, how to use the pens, clinical evidence for efficacy, side effects and safety considerations, how it compares to other treatments, and how to buy safely from a regulated UK online pharmacy. We also include practical lifestyle and diet tips to maximise outcomes and a comprehensive FAQ to answer common patient questions.

Introduction — why this guide matters

Obesity and overweight are common, complex medical conditions that increase the risk of type 2 diabetes, cardiovascular disease, some cancers and reduced quality of life. For many people, diet and exercise alone are not enough. Prescription medicines such as Saxenda (liraglutide) can be an effective adjunct to lifestyle changes for people who meet specific clinical criteria.

This guide is written for UK residents considering Saxenda and for those who want to understand the medicine, practical use of the pre-filled pens, safety, and how to obtain it safely and legally from a regulated pharmacy. It does not replace medical advice but provides in-depth, evidence-based information to guide discussions with your prescriber and pharmacist.

What is Saxenda (liraglutide)?

Saxenda is the brand name for a prescription medicine whose active ingredient is liraglutide. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a class of medications that mimic a naturally occurring gut hormone involved in appetite regulation and glucose control.

Saxenda is licensed in the UK for weight management in adults with a body mass index (BMI) of:

30 kg/m² or greater (obesity), or
27 kg/m² or greater (overweight) with at least one weight-related comorbidity (for example, high blood pressure, type 2 diabetes, dyslipidaemia).

It is supplied as a pre-filled multi-dose injection pen for once-daily subcutaneous (under the skin) injection. Saxenda is a higher-dose formulation of liraglutide than the formulation used for diabetes treatment (brand name Victoza).

How Saxenda works — the medical mechanism

Saxenda mimics GLP‑1, a hormone released by intestinal cells after eating. GLP‑1 receptor agonists act on multiple pathways to reduce body weight:

Appetite reduction: Activation of GLP‑1 receptors in the brain (hypothalamus and brainstem) increases feelings of satiety and reduces hunger, resulting in lower food intake.
Slowed gastric emptying: Liraglutide slows the rate at which the stomach empties, contributing to prolonged fullness after meals.
Metabolic effects: Improvements in glucose regulation and insulin sensitivity are observed, which is especially relevant for people with prediabetes or type 2 diabetes.

Because these mechanisms reduce caloric intake and support beneficial metabolic changes, Saxenda is used as an adjunct to a reduced-calorie diet and increased physical activity for sustained weight management.

Who is Saxenda suitable for?

Saxenda is prescription-only and is suitable for adults who meet specific clinical criteria. Typical indications include:

Adults with BMI ≥ 30 kg/m².
Adults with BMI ≥ 27 kg/m² with at least one weight-related condition (for example high blood pressure, dyslipidaemia, obstructive sleep apnoea, or type 2 diabetes).
Patients who are committed to combined medication and structured lifestyle changes (dietary modification, exercise and behavioural interventions).

It is not suitable for:

People with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
Pregnant or breastfeeding women.
Children and adolescents (unless under specific specialist supervision — Saxenda is licensed for adults).
People with known hypersensitivity to liraglutide or any excipients in the product.

Clinical efficacy — what the evidence shows

Saxenda’s effectiveness was evaluated in large randomised clinical trials collectively known as the SCALE programme. While individual trials differ, the key points are:

People treated with liraglutide 3.0 mg, alongside diet and exercise, achieve statistically and clinically significant weight loss compared with placebo.
Mean weight loss in the pivotal trials after around 56 weeks of treatment was substantially greater in the liraglutide group than placebo — typically in the low-to-mid single-digit percentages vs placebo; many patients achieved ≥5% and ≥10% weight loss.
Responders experienced improvements in cardiometabolic risk factors, including reductions in blood pressure, improvements in cholesterol profiles and a reduced progression from prediabetes to diabetes in some studies.

In practice, clinical trials recorded that a majority of patients on Saxenda achieved meaningful weight loss (≥5% body weight) when combined with lifestyle support, and a significant proportion achieved even greater weight reductions. As with all therapies, individual responses vary.

Dosage and administration — how to use the Saxenda pen

Dosage schedule

Saxenda is started at a low dose then escalated weekly to reduce gastrointestinal side effects. A common titration schedule is:

Week 1: 0.6 mg once daily
Week 2: 1.2 mg once daily
Week 3: 1.8 mg once daily
Week 4: 2.4 mg once daily
Week 5 and onwards: 3.0 mg once daily (maintenance dose)

If maintenance at 3.0 mg is not tolerated, a lower dose may be continued. If treatment is stopped for more than a few days, your prescriber may advise restarting at a lower dose and re-titrating.

Administration technique

Saxenda is given by subcutaneous injection once daily at any time of day, independently of meals.
Common injection sites: abdomen, thigh, or upper arm. Rotate injection sites regularly to reduce the risk of injection-site reactions and lipodystrophy.
Use a new single-use needle for each injection (needles are not supplied in some packs). After attaching the needle, dial the prescribed dose and inject; hold the pen pressed against the skin for the manufacturer-recommended time (typically several seconds) to ensure the full dose is delivered.
Do not share pens or needles. Sharing increases the risk of transmitting infections.
Follow the manufacturer’s leaflet for priming instructions and specific pen-handling steps. If unsure, ask your pharmacist or nurse to demonstrate.

Storage

Unopened pens: store in a refrigerator (2–8°C). Do not freeze. Protect from light.
After first use: advice varies by product leaflet but typically a pen can be kept at room temperature, protected from heat and light, for a limited period (for example, up to 30 days). Always confirm storage instructions on the specific product leaflet and with your pharmacist.

Common and serious side effects

All medicines can cause adverse effects. With Saxenda, the most common side effects are gastrointestinal and tend to be more troublesome during dose escalation:

Common side effects: nausea, vomiting, diarrhoea, constipation, abdominal pain, loss of appetite, dyspepsia. These are often transient and reduce with time or a slower dose titration.
Injection site reactions: redness, itching, small lumps at the injection site.
Tiredness or dizziness: some patients report low energy during the initial weeks.

Less common but serious risks:

Pancreatitis: there have been post-marketing reports of pancreatitis. Seek urgent medical advice if you experience severe abdominal pain (which may radiate to the back), persistent vomiting or fever.
Gallbladder disease: rapid weight loss and GLP‑1 receptor agonists can increase the risk of gallstones and cholecystitis.
Thyroid C‑cell tumours: liraglutide caused increased incidence of thyroid C‑cell tumours in rodents. Although a causal relationship in humans has not been established, Saxenda is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2.
Hypoglycaemia: when Saxenda is used with insulin or insulin secretagogues (e.g., sulfonylureas), the risk of low blood sugar increases — dose adjustments of the other agents may be needed.
Allergic reactions: rare but can be serious. Stop and seek medical help if you have a severe rash, difficulty breathing, or swelling of the face, tongue or throat.

Any new or worsening symptoms should be discussed with your prescriber or pharmacist. If you experience signs of serious adverse events (for example persistent severe abdominal pain suggestive of pancreatitis), seek urgent medical attention.

Precautions, contraindications and monitoring

Before starting Saxenda, your clinician will assess suitability and discuss monitoring:

Baseline assessment: weight and BMI measurement, medical history, current medications, screening for personal/family history of MTC/MEN2, pregnancy test in women of childbearing potential, and review of gastrointestinal and biliary disease history.
Concomitant medications: inform your clinician about all medicines, especially insulin, sulfonylureas, oral corticosteroids, or other medicines that affect blood glucose or body weight.
Pregnancy and breastfeeding: Saxenda must not be used during pregnancy or while breastfeeding. Women of childbearing age should use effective contraception and stop the medicine if planning pregnancy.
Renal impairment: use with caution in patients with severe renal impairment or end-stage renal disease; monitor for dehydration from vomiting/diarrhoea which can worsen renal function.
Elderly: limited data in very elderly patients; monitor closely for adverse events.

Follow-up appointments are important to review progress and tolerability. If after around 12 weeks at the full dose you have not lost at least 5% of baseline body weight, prescribers commonly re-evaluate continuation of therapy — this criterion is used in many trials and clinical guidelines to identify responders.

Comparisons with other weight loss treatments

Understanding how Saxenda compares to other treatments helps set expectations.

Saxenda vs semaglutide (Wegovy)

Both are GLP‑1 receptor agonists but semaglutide (Wegovy) is given once weekly and has generally produced larger average weight loss in clinical trials (often double-digit percentages for semaglutide vs mid-single-digit to low-double-digit percentages for liraglutide in comparable studies).
Semaglutide’s weekly dosing may be more convenient for some patients. Side-effect profiles are broadly similar (gastrointestinal), though individual tolerability varies.
Availability, NICE recommendations and NHS funding vary; cost and access differ between treatments.

Saxenda vs tirzepatide (dual GIP/GLP‑1 agents)

Tirzepatide (a dual GIP and GLP‑1 receptor agonist) has demonstrated even greater weight loss in trials compared with earlier GLP‑1s. As with semaglutide, real-world availability, cost and regulatory status on the NHS vary.
Safety and side-effect profiles differ; tirzepatide is newer and may have distinct considerations discussed with your clinician.

Saxenda vs orlistat and non-drug approaches

Orlistat (Alli/Xenical) works by reducing fat absorption and is available over-the-counter at low doses and on prescription at higher doses. Weight loss with orlistat is typically modest and side effects are mainly gastrointestinal with fatty stools and urgency.
Bariatric surgery produces the most dramatic and durable weight loss but requires surgical evaluation, has operative risks and lifelong nutritional follow-up.
Medication choice should consider magnitude of weight loss required, comorbidities, side effects, convenience and cost. Medication is usually adjunctive to structured lifestyle intervention.

Lifestyle support, diet and exercise — how to maximise results

Medicines like Saxenda are most effective when used alongside comprehensive lifestyle changes. Weight management is a long-term process that requires sustainable behavioural changes.

Dietary strategies

Create a moderate calorie deficit: safe weight loss typically starts with a daily calorie deficit of 500–700 kcal, leading to ~0.5–1 kg weight loss per week for many people. Avoid extreme calorie restriction which is hard to sustain.
Prioritise protein: include a high-quality protein source at each meal (lean meats, fish, eggs, beans, dairy) to support satiety and preserve lean mass during weight loss.
Increase fibre and vegetables: non-starchy vegetables, whole grains, legumes and fruit of choice provide bulk and satiety for fewer calories.
Limit liquid calories and sugary drinks: swap high-sugar beverages for water, unsweetened tea/coffee or sparkling water.
Mindful eating and portion control: eat slowly, avoid distractions, use smaller plates and plan meals in advance to reduce impulsive eating.

Physical activity

Follow UK guidance: aim for at least 150 minutes per week of moderate-intensity aerobic activity (or 75 minutes of vigorous activity) plus strength/resistance training on two or more days per week.
Include functional exercises and progressive resistance training to preserve muscle mass.
Increase incidental activity (walking, stair climbing) — small increases in daily movement add up.

Behavioural change and mental health

Set SMART goals (specific, measurable, achievable, relevant, time-bound).
Use structured programmes, counselling or behavioural therapy where available — behaviour support improves long-term outcomes.
Address emotional eating, stress and sleep — poor sleep and high stress make weight management harder.
Join support groups or specialist weight management services if accessible.

How to buy Saxenda safely in the UK — regulated online pharmacies and regulatory authorities

Saxenda is a prescription-only medicine in the UK. It must be supplied by a registered prescriber and dispensed by a pharmacy. If you are considering purchasing Saxenda online, use only regulated UK providers.

Key safety steps when buying online:

Ensure the online pharmacy is registered with the General Pharmaceutical Council (GPhC): GPhC registration means the pharmacy meets UK professional standards. Check the GPhC register (www.pharmacyregulation.org) to confirm registration and to view the pharmacy’s details.
Look for MHRA approvals and alerts: The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines in the UK and issues safety updates. Reputable pharmacies will comply with MHRA guidance and notify patients of safety information.
Do not buy from overseas or unverified websites: Unregulated suppliers may sell falsified or substandard medicines. Avoid websites that do not require a prescription, do not show contact details or lack a UK address.
Require a prescription and clinical screening: A legitimate UK online pharmacy will require a valid UK prescription or an online consultation with a prescriber who assesses suitability before issuing a private prescription.
Check the pharmacist is accessible: Reputable services provide contact details for a UK-registered pharmacist for counselling on use and side effects.
Read the patient information leaflet and storage instructions: Confirm product authenticity and expiry dates on receipt.

If in doubt, contact your local GP or community pharmacist. The NHS website has guidance on using online pharmacies safely.

Cost and NHS availability

NHS availability and funding of obesity medicines vary. Historically, routine NHS commissioning for drugs like liraglutide for weight management has been limited due to cost-effectiveness considerations. Private prescriptions are commonly used for access to Saxenda in the UK.

Talk to your GP about whether you are eligible for specialist weight management services in the NHS, and whether medication is appropriate. If you opt for private treatment, discuss costs, likely duration and monitoring plans with the clinic or prescriber.

Comprehensive FAQ — the questions patients ask most often

1. How quickly will I see weight loss on Saxenda?

Many people experience reduced appetite within the first 1–4 weeks. Significant weight loss tends to be gradual — meaningful reductions are commonly seen by 12 weeks and continue while the medication and lifestyle measures are maintained. Clinical assessments often check for at least 5% weight loss by 12 weeks at the full dose to identify responders.

2. How long do I need to take Saxenda?

Duration depends on individual goals, response and tolerability. Saxenda is intended as part of a long-term weight management strategy; stopping medication commonly leads to weight regain unless lifestyle changes are sustained. Your prescriber will advise on ongoing use, periodic review and whether continuation is appropriate.

3. Can Saxenda be used with diabetes medications?

Saxenda can affect glucose control. If you have type 2 diabetes and are taking insulin or sulfonylureas, your clinician may need to reduce doses to avoid hypoglycaemia. Saxenda is not a replacement for glucose-lowering therapy without specialist oversight.

4. Is Saxenda safe in pregnancy?

No. Saxenda must not be used during pregnancy or while breastfeeding. Women of childbearing potential should use effective contraception and stop the medicine if planning pregnancy, with alternative weight-management plans discussed with their clinician.

5. Will I get side effects?

The most common side effects are gastrointestinal (nausea, vomiting, diarrhoea, constipation) and often occur during dose escalation. Side effects typically improve over time. Serious but rare events include pancreatitis and gallbladder disease. Report new worrying symptoms to your prescriber.

6. Can children use Saxenda?

Saxenda is licensed for adults. Specialist paediatric advice is required for people under 18; use in children is not routine and should be under close specialist supervision if considered.

7. Can I share a pen with someone else?

No. Pens and needles must not be shared. Sharing increases the risk of infection transmission. Always use a new needle for each injection and dispose of needles in an appropriate sharps container.

8. What should I do if I miss a dose?

If you miss a dose, take it as soon as you remember on the same day and continue your next dose at the usual time the following day. Do not take extra doses to make up for a missed one. If you miss multiple doses, contact your prescriber for advice — they may advise restarting titration.

9. How should I store and dispose of the pens?

Store unopened pens in the fridge (2–8°C). After first use, follow leaflet instructions — many pens can be kept at room temperature (up to a defined temperature) for a limited time (for example 30 days) and then must be discarded. Dispose of used needles in a sharps bin and return or dispose of the full sharps container at designated community collection points or local pharmacy schemes.

10. What if I experience severe abdominal pain?

Severe, persistent abdominal pain (with or without vomiting) requires urgent medical assessment to exclude pancreatitis. Stop Saxenda and seek immediate medical help if this occurs.

Practical checklist before starting Saxenda

Obtain a medical assessment from an NHS or private prescriber who will confirm eligibility.
Discuss medical history, current medications and pregnancy plans.
Agree a titration schedule and plan for follow-up and monitoring.
Arrange access to diet, exercise and behaviour support (this may be through NHS services, private clinics or community programmes).
Ensure you know how to use the pen, store it correctly and dispose of needles safely.

Conclusion

Saxenda (liraglutide) is an evidence-based prescription treatment option for adults with obesity or clinically significant overweight with comorbidities, designed to be used alongside structured lifestyle interventions. It works by reducing appetite, slowing gastric emptying and improving metabolic markers. Clinical trials demonstrate meaningful weight loss in many patients, but responses vary and gastrointestinal side effects are common, particularly during dose escalation.

Deciding whether Saxenda is appropriate requires a thorough discussion with a prescriber about benefits, risks and practicalities. If you choose treatment, combine the medicine with sustainable dietary changes, physical activity and behavioural support for the best chance of durable results. Purchase only through regulated UK channels — ensure the online pharmacy is registered with the General Pharmaceutical Council (GPhC) and complies with guidance from the MHRA to reduce the risk of counterfeit or unsafe medicines.

Disclaimer

Important: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, changing or stopping any medicine. Follow the guidance of your prescriber and pharmacist, read the patient information leaflet supplied with the medicine, and contact emergency services if you experience a serious reaction or medical emergency.